Enrolment concludes in Biohaven’s RISE3 trial for epilepsy

Biohaven has concluded enrolment in the pivotal RISE3 Phase II/III trial assessing the selective Kv7.2/7.3 channel activator, opakalim, for refractory focal epilepsy. The trial enrolled adults with refractory focal onset seizures who were having at least four monthly seizures and one-to-three anti-seizure medicines. Credit: Antonio Marca/Shutterstock.com. Biohaven has concluded enrolment in the pivotal RISE3 Phase II/III trial assessing the selective Kv7.2/7.3 channel activator, opakalim (BHV-7000), for refractory focal epilepsy. Topline data from the double-blind, randomised, placebo-controlled trial is expected in the second half of 2026 (H2 2026). Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading…

Source: Clinical Trials Arena